207 related articles for article (PubMed ID: 34942546)
1. CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review.
Khan E; Shrestha AK; Elkhooly M; Wilson H; Ebbert M; Srivastava S; Wen S; Rollins S; Sriwastava S
J Neurol Sci; 2022 Jan; 432():120089. PubMed ID: 34942546
[TBL] [Abstract][Full Text] [Related]
2. Peripheral nervous system adverse events associated with immune checkpoint inhibitors.
Rossi S; Gelsomino F; Rinaldi R; Muccioli L; Comito F; Di Federico A; De Giglio A; Lamberti G; Andrini E; Mollica V; D'Angelo R; Baccari F; Zenesini C; Madia P; Raschi E; Cortelli P; Ardizzoni A; Guarino M
J Neurol; 2023 Jun; 270(6):2975-2986. PubMed ID: 36800019
[TBL] [Abstract][Full Text] [Related]
3. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature.
Boutros A; Bottini A; Rossi G; Tanda ET; Spagnolo F; Barletta G; Croce E; Fava P; Parisi A; De Rosa F; Palla M; Marconcini R; Ferrari M; Grandis M; Spallarossa P; Sarocchi M; Arboscello E; Del Mastro L; Lambertini M; Pronzato P; Genova C
ESMO Open; 2023 Feb; 8(1):100791. PubMed ID: 36791639
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
Reynolds KL; Guidon AC
Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
[TBL] [Abstract][Full Text] [Related]
5. Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors.
Farina A; Villagrán-García M; Ciano-Petersen NL; Vogrig A; Muñiz-Castrillo S; Taillandier L; Michaud M; Lefilliatre M; Wang A; Lepine Z; Picard G; Wucher V; Dhairi M; Fabien N; Goncalves D; Rogemond V; Joubert B; Honnorat J
Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36446613
[TBL] [Abstract][Full Text] [Related]
6. Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials.
Bruna J; Argyriou AA; Anastopoulou GG; Alemany M; Nadal E; Kalofonou F; Piulats JM; Simó M; Velasco R; Kalofonos HP
J Peripher Nerv Syst; 2020 Jun; 25(2):171-177. PubMed ID: 32166812
[TBL] [Abstract][Full Text] [Related]
7. Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management.
Farina A; Villagrán-García M; Honnorat J
Rev Neurol (Paris); 2023 Jun; 179(5):506-515. PubMed ID: 36934022
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit.
Deharo F; Carvelli J; Cautela J; Garcia M; Sarles C; Maues de Paula A; Bourenne J; Gainnier M; Bichon A
J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233479
[TBL] [Abstract][Full Text] [Related]
9. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
10. Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea.
Hyun JW; Kim KH; Kim SH; Kim HJ
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5583-5589. PubMed ID: 36495331
[TBL] [Abstract][Full Text] [Related]
11. Neurological toxicities associated with immune-checkpoint inhibitors.
Touat M; Talmasov D; Ricard D; Psimaras D
Curr Opin Neurol; 2017 Dec; 30(6):659-668. PubMed ID: 28938341
[TBL] [Abstract][Full Text] [Related]
12. Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years.
Ruggiero R; Balzano N; Di Napoli R; Fraenza F; Pentella C; Riccardi C; Donniacuo M; Tesorone M; Danesi R; Del Re M; Rossi F; Capuano A
Front Immunol; 2023; 14():1134436. PubMed ID: 37006303
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of immune checkpoint inhibitor-related neurological adverse events and association with anti-neuronal autoantibodies.
Salim A; Tapia Rico G; Shaikh A; Brown MP
Expert Opin Biol Ther; 2021 Sep; 21(9):1237-1251. PubMed ID: 33645372
[No Abstract] [Full Text] [Related]
14. Immune Checkpoint Inhibitors and Neurotoxicity.
Zhao Z; Zhang C; Zhou L; Dong P; Shi L
Curr Neuropharmacol; 2021; 19(8):1246-1263. PubMed ID: 33380303
[TBL] [Abstract][Full Text] [Related]
15. Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies.
Seki M; Kitano S; Suzuki S
Cancer Immunol Immunother; 2022 Apr; 71(4):769-775. PubMed ID: 34515815
[TBL] [Abstract][Full Text] [Related]
16. Neurological immune-related adverse events associated with immune checkpoint inhibitors: A review of the literature.
Fan S; Ren H; Zhao L; Yin J; Feng G; Wang J; Guan H
Asia Pac J Clin Oncol; 2020 Dec; 16(6):291-298. PubMed ID: 32893999
[TBL] [Abstract][Full Text] [Related]
17. Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice.
Villagrán-García M; Velasco R
Neurol Sci; 2022 Apr; 43(4):2339-2361. PubMed ID: 35175441
[TBL] [Abstract][Full Text] [Related]
18. Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review.
Marini A; Bernardini A; Gigli GL; Valente M; Muñiz-Castrillo S; Honnorat J; Vogrig A
Neurology; 2021 Apr; 96(16):754-766. PubMed ID: 33653902
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitors in Patients with Pre-existing Neurologic Autoimmune Disorders.
Aoun R; Gratch D; Kaminetzky D; Kister I
Curr Neurol Neurosci Rep; 2023 Nov; 23(11):735-750. PubMed ID: 37870664
[TBL] [Abstract][Full Text] [Related]
20. Neurological Manifestations Related to Immune Checkpoint Inhibitors: Reverse Translational Research by Using the European Real-World Safety Data.
Ruggiero R; Stelitano B; Fraenza F; di Mauro G; Scavone C; Sportiello L; Rafaniello C; Di Napoli R; Danesi R; Del Re M; Rossi F; Capuano A
Front Oncol; 2022; 12():824511. PubMed ID: 35372076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]